Results 141 to 150 of about 5,420 (200)
Some of the next articles are maybe not open access.
Elvitegravir for the treatment of HIV
Expert Opinion on Pharmacotherapy, 2016Current antiretrovirals (ARVs) have demonstrated the ability to prolong the life of an HIV infected individual via suppression of the virus and subsequent restoration of immune function. Despite significant advancement, there remains an opportunity for improvement.
Nathan R Unger, , Elizabeth Sherman
exaly +4 more sources
Elvitegravir: a once-daily inhibitor of HIV-1 integrase
Expert Opinion on Investigational Drugs, 2012Elvitegravir (EVG) is a potent inhibitor of HIV-1 integrase (IN) undergoing Phase III clinical trials. It blocks the strand-transfer step in a multi-step process that allows double-stranded cDNA to be irreversibly incorporated within the host DNA. It is the second member of the HIV-1 IN inhibitor class, following raltegravir.
Todd, Wills, Vivian, Vega
exaly +3 more sources
Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamide
Reactions Weekly, 2023semanticscholar +4 more sources
Journal of AOAC International, 2023
BACKGROUND Emtricitabine (ETC), Tenofovir disoproxil fumarate (TNF), Elvitegravir (EVG), and Cobicistat (CBS) are antiviral drugs used to treat human immunodeficiency virus (HIV) infections.
V. Singh, V. Singh, S. Daharwal
semanticscholar +1 more source
BACKGROUND Emtricitabine (ETC), Tenofovir disoproxil fumarate (TNF), Elvitegravir (EVG), and Cobicistat (CBS) are antiviral drugs used to treat human immunodeficiency virus (HIV) infections.
V. Singh, V. Singh, S. Daharwal
semanticscholar +1 more source
Antiviral Therapy, 2008
Background This crossover, open-label clinical study evaluated the potential for clinically relevant drug interactions between ritonavir-boosted elvitegravir (elvitegravir/r), an HIV integrase inhibitor, and etravirine, a non-nucleoside reverse transcriptase inhibitor.
Srinivasan, Ramanathan +4 more
openaire +2 more sources
Background This crossover, open-label clinical study evaluated the potential for clinically relevant drug interactions between ritonavir-boosted elvitegravir (elvitegravir/r), an HIV integrase inhibitor, and etravirine, a non-nucleoside reverse transcriptase inhibitor.
Srinivasan, Ramanathan +4 more
openaire +2 more sources